Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527015 | 1.00 | TDP1 (0.61) | TDP1KDM4EALOX15TSHRACMSD | |
| Hydrochloric Acid SCHEMBL29133272 | 0.98 | TDP1 (0.59) | TDP1KDM4EALOX15TSHRACMSD | |
| SCHEMBL2277413 | 0.98 | TDP1 (0.59) | TDP1KDM4EALOX15TSHRACMSD | |
| SCHEMBL27691146 | 0.93 | KDM4E (0.53) | TDP1KDM4EALOX15TSHRACMSD | |
| SCHEMBL18377809 | 0.89 | ECE1 (0.54) | TDP1KDM4EALOX15TSHRACMSD | |
| SCHEMBL31344569 | 0.87 | KDM4E (0.55) | TDP1KDM4EALOX15TSHRACMSD | |
| SCHEMBL8866132 | 0.86 | CTSA (0.45) | TDP1KDM4EALOX15TSHRACMSD | |
| SCHEMBL13454408 | 0.85 | KDM4E (0.57) | TDP1KDM4EALOX15TSHRACMSD | |
| SCHEMBL248517 | 0.84 | CTSA (0.44) | TDP1KDM4EALOX15TSHRACMSD | |
| SCHEMBL29858015 | 0.84 | CTSA (0.44) | TDP1KDM4EALOX15TSHRACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057575-A | Novel metal-organic framework supported catalyst, preparation method and photocatalytic CO thereof2Reduction application | 大连理工大学 | 2026-05-19 | — | — | CN | claimed |
| CN-118491563-A | Preparation method of metal-organic framework supported iridium-based catalyst and photocatalytic CO2Reduction application | 大连理工大学 | 2024-08-16 | — | — | CN | claimed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-112708256-B | Ultraviolet light aging resistant fluorescent TPU (thermoplastic polyurethane) film material as well as preparation method and application thereof | 宁波长阳科技股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-114890940-A | Synthetic method of 6-methoxy-2-picolinic acid | 嘉兴瑞驰生物科技有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-110467601-B | Pyrazole bipyridyl ketone compound, intermediate, preparation method and application thereof | 杭州市西溪医院 | 2021-07-02 | — | — | CN | claimed |
| CN-112708256-A | Ultraviolet light aging resistant fluorescent TPU (thermoplastic polyurethane) film material as well as preparation method and application thereof | 宁波长阳科技股份有限公司 | 2021-04-27 | — | — | CN | claimed |
| CN-110467601-A | A kind of pyrazoles bipyridyl ketone compounds, intermediate and preparation method and application | XIXI HOSPITAL OF HANGZHOU | 2019-11-19 | — | — | CN | claimed |
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | claimed |
| CN-104968657-A | Substituted triazole and imidazole compounds | HOFFMANN LA ROCHE | 2015-10-07 | — | — | CN | claimed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | claimed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | claimed |
| EP-2552918-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-02-06 | — | — | EP | claimed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | claimed |
| JP-2011529057-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| WO-2010011570-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | WO | claimed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | claimed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | TDP1 4713/4885KDM4E 3641/4885ALOX15 1712/4885 |
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | HDAC7, PSMB7, IKZF3 | TDP1 1665/4885KDM4E 865/4885ALOX15 3352/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | TDP1 1106/4885KDM4E 2749/4885ALOX15 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.